Zavesca added to CMS drug demo
Executive Summary
Coverage of Actelion/Celltech's oral Gaucher's disease therapy Zavesca (miglustat) has been added to the Medicare Part B drug replacement demonstration project, according to CMS. The demonstration project now provides for interim coverage of approximately 30 oral or self-injected replacements for physician-administered drugs. Enrollment in the project has been described as predictive of enrollment trends in the upcoming Part D benefit (1"The Pink Sheet" July 25, 2005, p. 26)...
You may also be interested in...
Medicare Oral Drug Demonstration A Dud; Will Part D Enrollment Take Off?
Enrollment challenges with the Medicare oral drug replacement demonstration project are highlighting possible stumbling blocks in the Part D implementation process
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.